表紙
市場調査レポート

Kolltan Pharmaceuticals, Inc.の製品パイプライン分析

Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 321340
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
Kolltan Pharmaceuticals, Inc.の製品パイプライン分析 Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日: 2016年02月29日 ページ情報: 英文 38 Pages
概要

Kolltan Pharmaceuticals, Inc.は米国に本社をおく製薬企業で、受容体型チロシンキナーゼを標的としたモノクローナル抗体製剤の開発を行っています。がんの既存治療薬を補完・強化する薬剤の開発を行っており、同社の薬剤候補であるKTN3379は、フェーズ1で抗腫瘍活性および薬物動態の試験中です。

当レポートでは、Kolltan Pharmaceuticals, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Kolltan Pharmaceuticals, Inc. の基本情報

  • Kolltan Pharmaceuticals, Inc. の概要
  • 主要情報
  • 企業情報

Kolltan Pharmaceuticals, Inc. :R&Dの概要

  • 主な治療範囲

Kolltan Pharmaceuticals, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Kolltan Pharmaceuticals, Inc. :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ
  • ■Kolltan Pharmaceuticals, Inc. :薬剤プロファイル
  • KTN-3379
  • KIT-ADC
  • KTN-0158
  • Monoclonal Antibody to Inhibit ALK for Cancer
  • Monoclonal Antibody to Inhibit c-MET for Cancer
  • Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis
  • Monoclonal Antibody to Inhibit FGFR4 for Cancer
  • Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection
  • Monoclonal Antibody to Inhibit RON for Cancer

Kolltan Pharmaceuticals, Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Kolltan Pharmaceuticals, Inc. :最新のパイプライン情報

Kolltan Pharmaceuticals, Inc. :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07974CDB

Summary

Global Markets Direct's, 'Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Kolltan Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kolltan Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Kolltan Pharmaceuticals, Inc.
  • The report provides overview of Kolltan Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Kolltan Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Kolltan Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Kolltan Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kolltan Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kolltan Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Kolltan Pharmaceuticals, Inc. Snapshot
    • Kolltan Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Kolltan Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Kolltan Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Kolltan Pharmaceuticals, Inc. - Pipeline Products Glance
    • Kolltan Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Kolltan Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Kolltan Pharmaceuticals, Inc. - Drug Profiles
    • KTN-0158
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KTN-3379
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KIT-SG3227
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KTN-0182A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Antagonize ALK Receptor for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Inhibit Axl for Cancer, Inflammation and Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target ErbB-3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit c-MET for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit FGFR4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit RON for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kolltan Pharmaceuticals, Inc. - Pipeline Analysis
    • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Target
    • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Kolltan Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Kolltan Pharmaceuticals, Inc., Key Information
  • Kolltan Pharmaceuticals, Inc., Key Facts
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Kolltan Pharmaceuticals, Inc. - Phase I, 2016
  • Kolltan Pharmaceuticals, Inc. - Preclinical, 2016
  • Kolltan Pharmaceuticals, Inc. - Discovery, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Kolltan Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Kolltan Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top